Correlation Between Morgan Stanley and Bridge Biotherapeutics

Can any of the company-specific risk be diversified away by investing in both Morgan Stanley and Bridge Biotherapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Morgan Stanley and Bridge Biotherapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Morgan Stanley Direct and Bridge Biotherapeutics, you can compare the effects of market volatilities on Morgan Stanley and Bridge Biotherapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Morgan Stanley with a short position of Bridge Biotherapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Morgan Stanley and Bridge Biotherapeutics.

Diversification Opportunities for Morgan Stanley and Bridge Biotherapeutics

-0.54

Correlation Coefficient

Morgan Stanley  Bridge Biotherapeutics

Excellent diversification

The 3 months correlation between Morgan and Bridge is -0.54. Overlapping area represents the amount of risk that can be diversified away by holding Morgan Stanley Direct and Bridge Biotherapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Bridge Biotherapeutics and Morgan Stanley is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Morgan Stanley Direct are associated (or correlated) with Bridge Biotherapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Bridge Biotherapeutics has no effect on the direction of Morgan Stanley i.e., Morgan Stanley and Bridge Biotherapeutics go up and down completely randomly.

Pair Corralation between Morgan Stanley and Bridge Biotherapeutics

Given the investment horizon of 90 days Morgan Stanley is expected to generate 83.49 times less return on investment than Bridge Biotherapeutics. But when comparing it to its historical volatility, Morgan Stanley Direct is 9.96 times less risky than Bridge Biotherapeutics. It trades about 0.01 of its potential returns per unit of risk. Bridge Biotherapeutics is currently generating about 0.12 of returns per unit of risk over similar time horizon. If you would invest  336,500  in Bridge Biotherapeutics on September 24, 2024 and sell it today you would earn a total of  57,500  from holding Bridge Biotherapeutics or generate 17.09% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	95.24%
Values	Daily Returns

Morgan Stanley Direct  vs.  Bridge Biotherapeutics

Morgan Stanley Direct

Risk-Adjusted Performance

8 of 100

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Morgan Stanley Direct are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. Despite quite unsteady fundamental indicators, Morgan Stanley may actually be approaching a critical reversion point that can send shares even higher in January 2025.

Bridge Biotherapeutics

Risk-Adjusted Performance

2 of 100

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Bridge Biotherapeutics are ranked lower than 2 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bridge Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Morgan Stanley and Bridge Biotherapeutics

The main advantage of trading using opposite Morgan Stanley and Bridge Biotherapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Morgan Stanley position performs unexpectedly, Bridge Biotherapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bridge Biotherapeutics will offset losses from the drop in Bridge Biotherapeutics' long position.

The idea behind Morgan Stanley Direct and Bridge Biotherapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the My Watchlist Analysis module to analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like.